In this month’s email, I offer two major updates relating to recent clinical evidence and guidelines. One highlights how a weekly basal insulin regimen could transform primary care nursing for people with type 2 diabetes who are frail. The other focuses on essential safety monitoring rules when prescribing 5-alpha reductase inhibitors (5-ARIs) for prostate health. Both provide crucial clinical guidance for daily practice.
1. Once-weekly insulin efsitora alfa – transforming type 2 diabetes management
Managing daily basal insulin injections in frail older patients often requires significant community nursing resources. The introduction of insulin efsitora alfa, a once-weekly basal insulin analogue evaluated across the QWINT clinical trial programme, offers a major shift in how we approach glycaemic control in primary care.
Key clinical findings
- Dosing and glycaemic efficacy: Insulin efsitora alfa is administered subcutaneously once weekly. The phase 3 QWINT trials demonstrated non-inferior HbA1c reduction compared with once-daily basal insulin (degludec or glargine) in adults with type 2 diabetes.
- Community nursing impact: For frail or housebound adults with type 2 diabetes requiring healthcare professional assistance solely for basal insulin administration, switching from daily basal insulin to once-weekly efsitora alfa reduces home visits from seven visits per week down to just one visit per week.
- Safety profile: Overall rates of severe or clinically significant hypoglycaemia were comparable to once-daily basal regimens across the type 2 diabetes trial populations.
Primary care takeaway
- Beyond glycaemic control, once-weekly basal insulin is expected to offer a dramatic reduction in district nursing burden, improved medication adherence and enhanced quality of life for frail patients reliant on community care visits.
For more detailed information, please see GPnotebook.
2. 5-ARIs monitoring and prostate cancer risk – the doubling rule in practice
5-ARIs – finasteride and dutasteride – are widely prescribed for benign prostatic hyperplasia and androgenetic alopecia. However, their profound impact on serum prostate-specific antigen (PSA) levels requires strict monitoring protocols to avoid missing underlying prostate cancer.
Key guidance and monitoring protocols
- The “doubling rule”: 5-ARIs reduce serum PSA by approximately 50% within 6 months of therapy. To correctly interpret PSA levels in patients taking a 5-ARI for 6 months or longer, clinicians must double the measured PSA value before comparing it with age-specific reference ranges.
- Establishing a new baseline: Obtain a baseline PSA prior to initiating 5-ARI therapy and repeat at 6 months to establish the patient’s new post-treatment baseline.
- Evaluating PSA rises: Any confirmed rise from the 6-month nadir PSA – even if the unadjusted value remains within the normal reference range – warrants urgent clinical evaluation and potential referral, as it may indicate non-compliance or underlying prostate malignancy.
- Detection bias and long-term outcomes: While trials (such as the Prostate Cancer Prevention Trial) initially reported a higher proportion of high-grade prostate cancers due to volume-reduction detection bias, long-term registry data confirm that 5-ARI use is not associated with increased prostate cancer-specific mortality.
- Medicines and Healthcare products Regulatory Agency safety warnings: Remind patients of potential persistent sexual dysfunction (e.g. erectile dysfunction and decreased libido) and neuropsychiatric effects (e.g. depression and suicidal ideation) associated with 5-ARIs.
Primary care takeaway
- Always check if a patient is taking finasteride or dutasteride when reviewing PSA results. Applying the “doubling rule” after 6 months of therapy and investigating any rise from the nadir are essential steps to ensure accurate prostate cancer screening.
For more detailed information, please see GPnotebook.
Other highlights in this month’s email include a summary of the GALEAS™ Bladder urine test and methylation biomarkers for bladder cancer, a Chikungunya haemorrhagic fever vaccine guidance update and an updated delirium section.